Abstract
BRAF, MEK and KIT point mutations are widely known for inducing resistance to targeted therapy in systemic treatment of advanced cutaneous melanoma. To explain this phenomenon different mechanisms are proposed, including tumoral genomic heterogeneity, both in primary and metastatic tumors. We have previously tested the heterogeneity hypothesis in primary cutaneous melanomas (acral lentigi…